tiprankstipranks
Advertisement
Advertisement

Balancing Near-Term Softness With GenAI-Driven Reacceleration: Why Salesforce Merits a Buy Ahead of Its Expected Growth Inflection

Balancing Near-Term Softness With GenAI-Driven Reacceleration: Why Salesforce Merits a Buy Ahead of Its Expected Growth Inflection

Keith Weiss, an analyst from Morgan Stanley, maintained the Buy rating on Salesforce. The associated price target remains the same with $287.00.

Meet Samuel – Your Personal Investing Prophet

Keith Weiss has given his Buy rating due to a combination of factors that balance near‑term softness with improving long‑term prospects. While underlying organic cRPO growth only met guidance and some areas like Marketing, Commerce, and Tableau weighed on results, Salesforce is demonstrating clear momentum in its GenAI initiatives, particularly through Agentforce and Data 360, which are scaling rapidly and showing strong expansion within the existing customer base.

Management also laid out a credible path to re‑accelerating growth, pointing to rising new net annualized order value in the second half of FY26 and a specific goal of achieving faster subscription growth by the second half of FY27. Combined with an enlarged $50 billion share repurchase authorization and a valuation of roughly 11x projected 2027 free cash flow, Weiss views the risk‑reward profile as attractive and believes it is worthwhile for investors to own the stock ahead of the anticipated inflection in growth.

In another report released today, Jefferies also maintained a Buy rating on the stock with a $250.00 price target.

Disclaimer & DisclosureReport an Issue

1